MC2 Therapeutics grants Almirall European commercial rights for psoriasis cream Wynzora
pharmafile | February 18, 2021 | News story | | Almirall, MC2 Therapeutics, psoriasis
Biopharma company Almirall and MC2 Therapeutics, a pharmaceutical company focused on therapies for autoimmune and chronic inflammatory conditions, have announced an agreement under which Almirall is granted exclusive European rights to commercialise MC2’s Wynzora Cream for treatment of plaque psoriasis.
In exchange, MC2 Therapeutics is eligible to receive upfront payments of €15 million, in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora Cream.
Wynzora Cream (calcipotriol and betamethasone as dipropionate) was approved by the FDA last July, and is currently under review in Europe supported by two Phase III trials, including an EU head-to-head trial against active comparator Dovobet/Daivobet Gel. The Physician Global Assessment treatment success, defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at week eight, was 51% for Wynzora Cream compared with 6% for vehicle.
Using MC2 Therapeutics’ PAD Technology, the cream was designed to provide patients a new treatment option in their daily routines by combining the three essentials of a topical therapy – high efficacy, a favourable safety profile, and convenience of use – in one single product.
Mike McClellan, Chief Financial Officer and interim CEO at Almirall, said: “We are thrilled with this agreement with MC2 Therapeutics. Wynzora Cream has demonstrated significant improvements in the skin clearance of psoriasis patients.
“It is the perfect addition to our growing psoriasis portfolio, which includes multiple treatment options, covering the whole spectrum of the disease. We are delighted that soon we will be able to offer this novel topical treatment to European dermatologists and their patients.”
Jesper J Lange, CEO of MC2 Therapeutics, also commented: “We are excited to partner with Almirall, an established company with deep expertise in dermatology and psoriasis and with the focus to improve patients’ needs.
“Bringing together Almirall’s excellence in commercial operations and MC2 Therapeutics’ commitment to ensure a global roll-out of Wynzora Cream we will, upon approval, ensure a strong launch of Wynzora Cream for the benefit of the many patients living with plaque psoriasis and for the healthcare practitioners who provide care.
“We believe that the unique combination of compelling clinical efficacy, a favourable safety profile, and treatment convenience are key components to treatment adherence and overall better patient satisfaction in topical treatment of plaque psoriasis in a real-world setting.”
Darcy Jimenez
Related Content
Boehringer Ingelheim’s Spevigo gains additional approvals in US and China
Boehringer Ingelheim has announced that Spevigo (spesolimab-sbzo) has been approved by the US Food and …
Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment
Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
Almirall has announced that the European Commission (EC) has approved Ebglyss (lebrikizumab) for the treatment …
